Arqule Early Cancer Study Shows Progress
13th Nov 2006, 16:15 GMT
Biotech company Arqule said interim results of an early-stage antitumor drug trial showed positive results, lifting the company's stock.
Arqule Early Cancer Study Shows Progress related news:
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- A transmission electron micrograph shows a prostate cancer cell. ... — Top Stories Photos - Reuters on Yahoo! News Photos
- Novel Vaccine Shows Promise Against Early-stage Breast Cancer — ScienceDaily Headlines
- Anti-cancer drug shows early promise in pulmonary hypertension — EurekAlert! - Breaking News
- Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up — Prostate Cancer and Prostatic Diseases
- Red Meat May Up Breast Cancer Risk — WebMD Health Headlines
- Study reveals women find cancer caring a heavier burden than men — EurekAlert! - Breaking News
- Shorter-course Radiation Treatment Safe For Breast Cancer — Health News from Medical News Today
- Mayo Clinic study observes normal aging process lowers breast cancer risk — EurekAlert! - Breaking News
- Promising vaccine for early breast cancer — United Press International - Health Business
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Tanox shares soar in wake of Genentech buyout